Heart disease remains the leading cause of death in the United States, with cardiovascular disease accounting for more than 940,000 deaths in 2022, according to the American Heart Association. The problem is worsening, and annual healthcare costs for cardiovascular conditions are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050. Into this growing crisis steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics, and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
What makes Cardio Diagnostics’ approach distinct is its ability to detect coronary heart disease earlier and with high sensitivity. The company’s recent commercial and regulatory milestones give additional shape to the investment thesis. The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the condition.
Cardio Diagnostics’ technology uses epigenetic markers—chemical modifications to DNA that can indicate disease risk—combined with AI-driven analysis to identify coronary heart disease from a simple blood test. This approach could potentially detect disease earlier than traditional methods such as stress tests or imaging, which often miss early-stage or atypical presentations. The company’s platform is designed to be accessible, requiring only a blood draw, and could be integrated into routine primary care screenings.
The company’s recent milestones include commercial launches and regulatory progress. For investors, the company’s positioning in a massive and growing market is a key consideration. The forward-looking statements in the company’s announcements highlight the potential, but also the risks, including those set forth under "Risk Factors" in the company’s SEC filings. More information can be found in the company’s newsroom at https://ibn.fm/CDIO and full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
